Treatment of impulse control disorders in Parkinsons disease: Practical considerations and future directions

Expert Review of Neurotherapeutics

Volumn 16, Issue 4, 2016, Pages 389-399

  Ramirez Zamora, Adolfo ^a   Gee, Lucy ^a   Boyd, James ^b   Biller, José ^c  

^a ALBANY MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^c LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

Compulsive eating and shopping; Dopamine Dysregulation Syndrome; Hypersexuality; Impulse control disorders; Parkinson's disease; Pathological gambling; Punding; STN DBS

Indexed keywords

AMANTADINE; ANTIANDROGEN; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; APOMORPHINE; ATYPICAL ANTIPSYCHOTIC AGENT; CARBIDOPA; CARBIDOPA PLUS LEVODOPA; LEVODOPA; NALOXONE; OPIATE ANTAGONIST; RASAGILINE; ROTIGOTINE; DOPAMINE RECEPTOR STIMULATING AGENT;

ANTIANDROGEN THERAPY; BRAIN DEPTH STIMULATION; COGNITIVE THERAPY; COMORBIDITY; CONTINUOUS INFUSION; DRUG TOLERABILITY; ENTERAL DRUG ADMINISTRATION; HUMAN; IMPULSE CONTROL DISORDER; MULTICENTER STUDY (TOPIC); PARKINSON DISEASE; PATHOPHYSIOLOGY; PERSONALIZED MEDICINE; PHARMACEUTICAL CARE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SOCIAL SUPPORT; SUBTHALAMIC DEEP BRAIN STIMULATION; COMPLICATION; DISEASE MANAGEMENT; DISRUPTIVE, IMPULSE CONTROL, AND CONDUCT DISORDERS;

DISEASE MANAGEMENT; DISRUPTIVE, IMPULSE CONTROL, AND CONDUCT DISORDERS; DOPAMINE AGONISTS; HUMANS; PARKINSON DISEASE;

EID: 84961210826     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.2016.1158103     Document Type: Review

References (76)

1. Voon V, Fox SH. Medication-related impulse control and repetitive behaviors in Parkinson disease. Arch Neurol. 2007;64(8):1089-1096.
2. Giovannoni G, O'Sullivan JD, Turner K, et al. Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry. 2000;68(4):423-428.
3. Lim SY, Evans AH, Miyasaki JM. Impulse control and related disorders in Parkinson's disease: review. Ann N Y Acad Sci. 2008;1142:85-107.
4. Phu AL, Xu Z, Brakoulias V, et al. Effect of impulse control disorders on disability and quality of life in Parkinson's disease patients. J Clin Neurosci. 2014;21(1):63-66.
5. Leroi I, Harbishettar V, Andrews M, et al. Carer burden in apathy and impulse control disorders in Parkinson's disease. Int J Geriatr Psychiatry. 2012;27(2):160-166.
6. Baumann-Vogel H, Valko PO, Eisele G, et al. Impulse control disorders in Parkinson's disease: don't set your mind at rest by selfassessments. Eur J Neurol. 2015;22:603-609.
7. Weintraub D, Siderowf AD, Potenza MN, et al. Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol. 2006;63(7):969-973.
8. Voon V, Sohr M, Lang AE, et al. Impulse control disorders in Parkinson disease: a multicenter case-control study. Ann Neurol. 2011;69(6):986-996.
9. Lee JY, Kim JM, Kim JW, et al. Association between the dose of dopaminergic medication and the behavioral disturbances in Parkinson disease. Parkinsonism Relat Disord. 2010;16(3):202-207.
10. Delaney M, Leroi I, Simpson J, et al. Impulse control disorders in Parkinson's disease: a psychosocial perspective. J Clin Psychol Med Settings. 2012;19(3):338-346.
11. Perez-Lloret S, Rey MV, Fabre N, et al. Prevalence and pharmacological factors associated with impulse-control disorder symptoms in patients with Parkinson disease. Clin Neuropharmacol. 2012;35 (6):261-265.
12. Weintraub D, Sohr M, Potenza MN, et al. Amantadine use associated with impulse control disorders in Parkinson disease in crosssectional study. Ann Neurol. 2010;68(6):963-968.
13. Voon V, Thomsen T, Miyasaki JM, et al. Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease. Arch Neurol. 2007;64(2):212-216.
14. Wu K, Politis M, O'Sullivan SS, et al. Single versus multiple impulse control disorders in Parkinson's disease: an (11)C-raclopride positron emission tomography study of reward cueevoked striatal dopamine release. J Neurol. 2015;262(6):1504-1514.
15. Potenza MN, Voon V, Weintraub D. Drug Insight: impulse control disorders and dopamine therapies in Parkinson's disease. Nat Clin Pract Neurol. 2007;3(12):664-672.
16. Gallagher DA, O'Sullivan SS, Evans AH, et al. Pathological gambling in Parkinson's disease: risk factors and differences from dopamine dysregulation. An analysis of published case series. Move Disord: Off J Move Disord Soc. 2007;22(12):1757-1763.
17. Weintraub D. Dopamine and impulse control disorders in Parkinson's disease. Ann Neurol. 2008;64(Suppl 2):S93-100.
18. Giugni JC, Tschopp L, Escalante V, et al. Dose-dependent impulse control disorders in piribedil overdose. Clin Neuropharmacol. 2012;35(1):49-50.
19. Tschopp L, Salazar Z, Gomez Botello MT, et al. Impulse control disorder and piribedil: report of 5 cases. Clin Neuropharmacol. 2010;33(1):11-13.
20. Micheli FE, Giugni JC, Espinosa ME, et al. Piribedil and pathological gambling in six parkinsonian patients. Arq Neuropsiquiatr. 2015;73 (2):115-118.
21. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med. 1988;318 (14):876-880.
22. Weintraub D, Koester J, Potenza MN, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol. 2010;67(5):589-595.
23. Napier TC, Corvol JC, Grace AA, et al. Linking neuroscience with modern concepts of impulse control disorders in Parkinson's disease. Move Disord: Off J Move Disord Soc. 2015;30(2):141-149.
24. Carriere N, Lopes R, Defebvre L, et al. Impaired corticostriatal connectivity in impulse control disorders in Parkinson disease. Neurology. 2015;84(21):2116-2123.
25. Rabinak CA, Nirenberg MJ. Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol. 2010;67(1):58-63.
26. Mamikonyan E, Siderowf AD, Duda JE, et al. Long-term follow-up of impulse control disorders in Parkinson's disease. Mov Disord. 2008;23(1):75-80.
27. Sohtaoglu M, Demiray DY, Kenangil G, et al. Long term follow-up of Parkinson's disease patients with impulse control disorders. Parkinsonism Relat Disord. 2010;16(5):334-337.
28. Mestre TA, Strafella AP, Thomsen T, et al. Diagnosis and treatment of impulse control disorders in patients with movement disorders. Ther Adv Neurol Disord. 2013;6(3):175-188.
29. Okai D, Samuel M, Askey-Jones S, et al. Impulse control disorders and dopamine dysregulation in Parkinson's disease: a broader conceptual framework. Eur J Neurol. 2011;18(12):1379-1383.
30. Garcia-Ruiz PJ, Martinez Castrillo JC, Alonso-Canovas A, et al. Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study. J Neurol Neurosurg Psychiatry. 2014;85(8):840-844.
31. Hauser RA, Hsu A, Kell S, et al. Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial. Lancet Neurol. 2013;12 (4):346-356.
32. Evans AH, Pavese N, Lawrence AD, et al. Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann Neurol. 2006;59(5):852-858.
33. Catalan MJ, De Pablo-Fernandez E, Villanueva C, et al. Levodopa infusion improves impulsivity and dopamine dysregulation syndrome in Parkinson's disease. Move Disord: Off J Move Disord Soc. 2013;28(14):2007-2010.
34. Todorova A, Samuel M, Brown RG, et al. Infusion therapies and development of impulse control disorders in advanced Parkinson disease: clinical experience after 3 years' follow-up. Clin Neuropharmacol. 2015;38(4):132-134.
35. Cilia R, Siri C, Canesi M, et al. Dopamine dysregulation syndrome in Parkinson's disease: from clinical and neuropsychological characterisation to management and long-term outcome. J Neurol Neurosurg Psychiatry. 2014;85(3):311-318.
36. Olanow CW, Kieburtz K, Odin P, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, doubleblind, double-dummy study. Lancet Neurol. 2014;13(2):141-149.
37. Cannas A, Solla P, Marrosu MG, et al. Dopamine dysregulation syndrome in Parkinson's disease patients on duodenal levodopa infusion. Move Disord: Off J Move Disord Soc. 2013;28(6):840-841.
38. Chang FC-F, K V, Van der Poorten D, et al. Levodopa-carbidopa intestinal gel infusion improves motor performance and quality of life in patients with advanced Parkinson's disease. J Clin Neurosci. 2014;21(11):2033.
39. Rizos A-M-MP, Martin A, European multicentre survey of tolerability rates and impulse control behaviour trends of prolonged release dopamine agonists in young and old PD. Move Disord: Off J Move Disord Soc. 2012;27(Suppl 1):S:50.
40. Schreglmann SR, Gantenbein AR, Eisele G, et al. Transdermal rotigotine causes impulse control disorders in patients with restless legs syndrome. Parkinsonism Relat Disord. 2012;18(2):207-209.
41. Samuel M, Rodriguez-Oroz M, Antonini A, et al. Management of impulse control disorders in Parkinson's disease: Controversies and future approaches. Move Disord: Off J Move Disord Soc. 2015;30 (2):150-159.
42. Garcia Ruiz PJ, Sesar Ignacio A, Ares Pensado B, et al. Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: a multicenter study. Move Disord: Off J Move Disord Soc. 2008;23(8):1130-1136.
43. Martinez-Martin P, Reddy P, Katzenschlager R, et al. EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson's disease. Move Disord: Off J Move Disord Soc. 2015;30(4):510-516.
44. Thomas A, Bonanni L, Gambi F, et al. Pathological gambling in Parkinson disease is reduced by amantadine. Ann Neurol. 2010;68 (3):400-404.
45. Walsh RA, Lang AE. Multiple impulse control disorders developing in Parkinson's disease after initiation of amantadine. Mov Disord. 2012;27(2):326.
46. Fasano A, Ricciardi L, Pettorruso M, et al. Management of punding in Parkinson's disease: an open-label prospective study. J Neurol. 2011;258(4):656-660.
47. Kashihara K, Imamura T. Amantadine may reverse punding in Parkinson's disease-observation in a patient. Mov Disord. 2008;23 (1):129-130.
48. McElroy SL, Nelson EB, Welge JA, et al. Olanzapine in the treatment of pathological gambling: a negative randomized placebo-controlled trial. J Clin Psychiatry. 2008;69(3):433-440.
49. Smith N, Kitchenham N, Bowden-Jones H. Pathological gambling and the treatment of psychosis with aripiprazole: case reports. Br J Psychiatry: J Ment Sci. 2011;199(2):158-159.
50. Miwa H, Morita S, Nakanishi I, et al. Stereotyped behaviors or punding after quetiapine administration in Parkinson's disease. Parkinsonism Relat Disord. 2004;10(3):177-180.
51. Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. Jama. 2014;311(16):1670-1683.
52. Hardwick A, Ward H, Hassan A, et al. Clozapine as a potential treatment for refractory impulsive, compulsive, and punding behaviors in Parkinson's disease. Neurocase. 2013;19(6):587-591.
53. Bonfils NA, Benyamina A, Aubin HJ, et al. Clozapine use for refractory impulse control disorders in Parkinson's disease: a case report. Psychopharmacology (Berl). 2015;232(19):3677-3679.
54. Sriram A, Ward HE, Hassan A, et al. Valproate as a treatment for dopamine dysregulation syndrome (DDS) in Parkinson's disease. J Neurol. 2013;260(2):521-527.
55. Hicks CW, Pandya MM, Itin I, et al. Valproate for the treatment of medication-induced impulse-control disorders in three patients with Parkinson's disease. Parkinsonism Relat Disord. 2011;17(5):379-381.
56. Epstein J, Madiedo CJ, Lai L, et al. Successful treatment of dopamine dysregulation syndrome with valproic acid. J Neuropsychiatry Clin Neurosci. 2014;26(3):E3.
57. Bermejo PE. Topiramate in managing impulse control disorders in Parkinson's disease. Parkinsonism Relat Disord. 2008;14(5):448-449.
58. Bermejo PE, Ruiz-Huete C, Anciones B. Zonisamide in managing impulse control disorders in Parkinson's disease. J Neurol. 2010;257 (10):1682-1685.
59. Bosco D, Plastino M, Colica C, et al. Opioid antagonist naltrexone for the treatment of pathological gambling in Parkinson disease. Clin Neuropharmacol. 2012;35(3):118-120.
60. Bortolato M, Cannas A, Solla P, et al. Finasteride attenuates pathological gambling in patients with Parkinson disease. J Clin Psychopharmacol. 2012;32(3):424-425.
61. Okai D, Askey-Jones S, Samuel M, et al. Trial of CBT for impulse control behaviors affecting Parkinson patients and their caregivers. Neurology. 2013;80(9):792-799.
62. Isaias IU, Siri C, Cilia R, et al. The relationship between impulsivity and impulse control disorders in Parkinson's disease. Move Disord: Off J Move Disord Soc. 2008;23(3):411-415.
63. Moum SJ, Price CC, Limotai N, et al. Effects of STN and GPi deep brain stimulation on impulse control disorders and dopamine dysregulation syndrome. PLoS One. 2012;7(1):e29768.
64. Lhommee E, Klinger H, Thobois S, et al. Subthalamic stimulation in Parkinson's disease: restoring the balance of motivated behaviours. Brain. 2012;135(Pt 5):1463-1477.
65. Shotbolt P, Moriarty J, Costello A, et al. Relationships between deep brain stimulation and impulse control disorders in Parkinson's disease, with a literature review. Parkinsonism Relat Disord. 2012;18 (1):10-16.
66. Amami P, Dekker I, Piacentini S, et al. Impulse control behaviours in patients with Parkinson's disease after subthalamic deep brain stimulation: de novo cases and 3-year follow-up. J Neurol Neurosurg Psychiatry. 2015;86(5):562-564.
67. Gee L, Smith H, De La Cruz P, et al The influence of bilateral subthalamic nucleus deep brain stimulation on impulsivity and prepulse inhibition in Parkinson's disease patients. Stereotact Funct Neurosurg. 2015;93(4):265-270.
68. Ardouin C, Voon V, Worbe Y, et al. Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation. Mov Disord. 2006;21(11):1941-1946.
69. Bandini F, Primavera A, Pizzorno M, et al. Using STN DBS and medication reduction as a strategy to treat pathological gambling in Parkinson's disease. Parkinsonism Relat Disord. 2007;13(6):369-371.
70. Witjas T, Baunez C, Henry JM, et al. Addiction in Parkinson's disease: impact of subthalamic nucleus deep brain stimulation. Mov Disord. 2005;20(8):1052-1055.
71. Knobel D, Aybek S, Pollo C, et al. Rapid resolution of dopamine dysregulation syndrome (DDS) after subthalamic DBS for Parkinson disease (PD): a case report. Cogn Behav Neurol: Off J Soc Behav Cogn Neurol. 2008;21(3):187-189.
72. Halbig TD, Tse W, Frisina PG, et al. Subthalamic deep brain stimulation and impulse control in Parkinson's disease. Eur J Neurol. 2009;16(4):493-497.
73. Murata M, Hasegawa K, Kanazawa I, et al. Zonisamide improves wearing-off in Parkinson's disease: A randomized, double-blind study. Move Disord: Off J Move Disord Soc. 2015;30(10):1343-1350.
74. Seppi K, Weintraub D, Coelho M, et al. The Movement Disorder Society Evidence-Based Medicine Review Update: treatments for the non-motor symptoms of Parkinson's disease. Mov Disord. 2011;26(Suppl 3):S42-80.
75. Kalivas PW, Volkow ND. The neural basis of addiction: a pathology of motivation and choice. Am J Psychiatry. 2005;162 (8):1403-1413.
76. Hamilton J, Lee J, Canales JJ. Chronic unilateral stimulation of the nucleus accumbens at high or low frequencies attenuates relapse to cocaine seeking in an animal model. Brain Stimul. 2015;8(1):57-63.